Company research
CorMedix Inc.
CIK 1410098Updated Nov 14, 2026
SecurityCRMD · NASDAQ · equity
Historical securities (1)
CRMD.WS · NYSE_AMERICAN · warrant · closed Apr 30, 2015CRMD price & chart
Loading TradingView…
NASDAQ:CRMD on TradingView ↗About the company
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional care settings in the U.S. and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
In the news
Today's Stocks in the News ↗
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update News provided by Talphera, Inc. Nov 12, 2025, 16:05 ET Share this article Share to X Share this article Share to X Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash a ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
DEFA14A filing
Regulation FD Disclosure
Items 7.01, 9.01
DEFA14A filing
Show 5 more recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 750,861,478Source | 77,586,194Source | 904,052,000Source | 252,599,103Source | 57,730,594Source | 815,637,000Source | 149,582,766Source | 68,023,742Source | 826,142,000Source | 118,845,673Source | 82,059,957Source | 62,038,259Source |
| Property, Plant and Equipment, NetUSD | 4,347,360Source | 1,899,875Source | 7,852,000Source | 1,641,152Source | 1,915,569Source | 6,166,000Source | 1,728,199Source | 1,905,704Source | 5,959,000Source | 1,828,016Source | 1,866,224Source | 1,609,679Source |
| GoodwillUSD | 17,515,265Source | — | 30,002,000Source | — | — | 30,002,000Source | — | — | 30,002,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 390,011,711Source | 1,896,104Source | 358,472,000Source | 1,740,260Source | — | 368,772,000Source | 1,792,208Source | — | 379,072,000Source | 1,844,156Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 48,493,076Source | 35,286,138Source | 256,692,000Source | 159,309,000Source | 28,540,633Source | 178,087,000Source | 66,286,000Source | 35,180,529Source | 144,837,000Source | 40,650,770Source | 43,642,684Source | 43,148,323Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 158,574,116Source | 17,387,446Source | 161,305,000Source | 42,911,634Source | 206,337Source | 154,807,000Source | 54,611,147Source | — | 171,233,000Source | 51,653,583Source | — | — |
| Inventory, NetUSD | 28,916,616Source | 6,649,495Source | 38,583,000Source | 9,634,438Source | 4,011,560Source | 30,731,000Source | 7,487,708Source | 2,320,396Source | 29,716,000Source | 7,599,535Source | 2,106,345Source | — |
| Assets, CurrentUSD | 259,535,273Source | 73,154,269Source | 480,554,000Source | 248,056,889Source | 53,194,379Source | 383,113,000Source | 144,861,576Source | 63,409,566Source | 367,051,000Source | 114,575,436Source | 79,450,400Source | 59,551,175Source |
| Prepaid Expense and Other Assets, CurrentUSD | 16,327,730Source | 2,916,889Source | 23,974,000Source | 4,675,885Source | 3,139,022Source | 19,488,000Source | 5,124,924Source | 2,166,267Source | 17,571,000Source | 3,481,868Source | 882,214Source | 623,672Source |
| Operating Lease, Right-of-Use AssetUSD | 3,173,567Source | 530,862Source | — | 413,652Source | 568,168Source | — | 453,633Source | 604,634Source | 3,020,000Source | 492,697Source | 640,278Source | 775,085Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 376,732,072Source | 18,873,926Source | 443,219,000Source | 31,968,916Source | 11,546,663Source | 378,588,000Source | 34,694,718Source | 10,011,022Source | 420,835,000Source | 34,188,723Source | 11,917,528Source | 6,978,523Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 92Source | 182Source | 0Source | 92Source | 182Source | 0Source | 92Source | 182Source | — | 137Source | 182Source | 182Source |
| Common Stock, Value, IssuedUSD | 78,350Source | 57,886Source | 78,000Source | 74,621Source | 55,274Source | 78,000Source | 67,711Source | 54,959Source | 79,000Source | 64,411Source | 54,938Source | 42,815Source |
| Additional Paid in CapitalUSD | 564,558,498Source | 411,659,517Source | 572,739,000Source | 519,634,193Source | 396,360,369Source | 574,943,000Source | 433,721,824Source | 394,040,254Source | 581,800,000Source | 424,131,789Source | 391,693,214Source | 330,294,782Source |
| Retained Earnings (Accumulated Deficit)USD | -190,595,174Source | -353,094,437Source | -111,986,000Source | -299,158,154Source | -350,317,625Source | -137,974,000Source | -318,986,135Source | -336,166,136Source | -176,575,000Source | -339,630,033Source | -321,700,013Source | -275,360,786Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 87,640Source | 89,120Source | 2,000Source | 79,435Source | 85,731Source | 2,000Source | 84,556Source | 83,461Source | 3,000Source | 90,646Source | 94,108Source | 82,743Source |
| Stockholders' Equity Attributable to ParentUSD | 374,129,406Source | 58,712,268Source | 460,833,000Source | 220,631,000Source | 46,183,931Source | 437,049,000Source | 114,888,000Source | 58,012,720Source | 405,307,000Source | 84,656,950Source | 70,142,429Source | 55,059,736Source |
| Liabilities and EquityUSD | 750,861,478Source | 77,586,194Source | 904,052,000Source | 252,599,103Source | 57,730,594Source | 815,637,000Source | 149,582,766Source | 68,023,742Source | 826,142,000Source | 118,845,673Source | 82,059,957Source | 62,038,259Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 133,643,797Source | 18,480,959Source | 187,396,000Source | 31,710,843Source | 11,111,417Source | 128,776,000Source | 34,390,626Source | 9,534,434Source | 174,269,000Source | 33,839,632Source | 11,400,515Source | 6,310,891Source |
| Operating Lease, Liability, CurrentUSD | 844,431Source | 163,449Source | — | 177,172Source | 159,077Source | — | 172,495Source | 154,801Source | 853,000Source | 167,922Source | 150,619Source | 134,801Source |
| Accounts Payable, CurrentUSD | 20,454,367Source | 1,343,833Source | 10,238,000Source | 5,815,366Source | 3,344,803Source | 12,827,000Source | 1,933,136Source | 2,826,322Source | 7,884,000Source | 1,720,177Source | 4,279,679Source | 2,202,149Source |
| Operating Lease, Liability, NoncurrentUSD | 2,411,243Source | 392,967Source | — | 258,073Source | 435,246Source | — | 304,092Source | 476,588Source | 2,253,000Source | 349,091Source | 517,013Source | 667,632Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 109,091,898Source | 16,973,677Source | 173,244,000Source | 25,718,305Source | 7,607,537Source | 112,773,000Source | 32,284,995Source | 6,553,311Source | 161,921,000Source | 31,951,533Source | 6,970,217Source | 3,973,941Source |
| Short-term InvestmentsUSD | 7,223,735Source | 10,743,562Source | 0Source | 31,402,850Source | 17,069,660Source | 0Source | 11,216,989Source | 23,370,989Source | 3,694,000Source | 11,036,857Source | 32,388,130Source | 15,644,062Source |
| Deferred Income Tax Liabilities, Net | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss | — | — | —Source | — | — | —Source | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 4,065,541Source | 1,227,476Source | 4,084,000Source | 2,677,000Source | 4,582,000Source | 3,500,000Source | 13,832,000Source | 6,129,408Source | 5,493,751Source | 4,069,520Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -16,445,000Source | 2,965,000Source | 90,924,000Source | 51,790,583Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,015,000Source | -112,000Source | 3,478,000Source | 5,493,190Source | 2,106,345Source | -3,008Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 4,943,000Source | 213,000Source | 3,329,000Source | -2,559,491Source | 2,077,479Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | -59,700,000Source | — | — | — | 12,964,000Source | 0Source | -25,797,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 42,382,000Source | 19,737,000Source | 175,046,000Source | -50,614,653Source | -38,409,480Source | -24,356,732Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 308,511,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,965,000Source | -195,000Source | -308,430,000Source | 21,230,713Source | -17,061,685Source | -3,709,364Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 729,000Source | 10,000Source | 2,260,000Source | 115,730Source | 327,300Source | 219,360Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 1,527,000Source | 1,019,000Source | 1,988,000Source | 289,622Source | 198,443Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -12,097,000Source | 6,093,000Source | 238,453,000Source | 26,318,595Source | 55,916,804Source | 17,898,241Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 33,250,000Source | 25,635,000Source | 105,069,000Source | -3,067,054Source | 448,447Source | -10,176,532Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 49,481,309Source | 35,391,222Source | 257,680,000Source | 159,414,000Source | 179,075,000Source | 66,391,000Source | 145,825,000Source | 40,756,138Source | 43,823,192Source | 43,374,745Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,817,000Source | 10,000Source | 17,000Source | 36,405Source | 34,296Source | 26,516Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 62,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 0Source | 0Source | — | -1,709Source | 2,808Source | -8,677Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 398,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 3,600,000Source | — | — | — | — | 51,948Source | 13,872,000Source | 155,844Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | 109,994Source | 677,000Source | 153,937Source | 70,755Source | 84,618Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -72,727Source | -33,325Source | — | -16,295Source | — | -38,172Source | -52,000Source | -30,788Source | -28,994Source | 37,145Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | 86,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 25,451,017Source | 6,580,834Source | 15,085,000Source | 9,504,000Source | 21,720,000Source | 9,693,000Source | 68,220,000Source | 29,959,150Source | — | — |
| GoodwillUSD | — | — | 17,515,265Source | — | 30,002,000Source | — | 30,002,000Source | — | 30,002,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | 2,029,000Source | — | — | 1,700,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -46,339,227Source | — |
| Income Tax Expense (Benefit)USD | — | — | -55,986,802Source | — | 12,745,000Source | 522,000Source | 17,044,000Source | 0Source | -13,039,000Source | -1,394,770Source | — | -585,617Source |
| InterestExpenseNonoperatingUSD | — | — | 948,242Source | 10,007Source | — | 6,671Source | — | 10,007Source | 2,782,000Source | 36,405Source | — | — |
| Investment Income, InterestUSD | — | — | 1,560,272Source | 553,856Source | — | 828,949Source | — | 566,797Source | 3,846,000Source | 2,578,792Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 3,090,909Source | — | 2,546,000Source | 0Source | -3,546,000Source | 0Source | 5,364,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 108,562,980Source | -2,776,812Source | 25,988,000Source | 19,828,000Source | 38,601,000Source | 20,644,000Source | 163,055,000Source | -17,930,020Source | -46,339,227Source | -29,701,705Source |
| Nonoperating Income (Expense)USD | — | — | 1,230,212Source | 510,524Source | -4,177,000Source | 806,000Source | -8,013,000Source | 519,000Source | -125,000Source | 3,031,599Source | — | — |
| Operating ExpensesUSD | — | — | 41,734,707Source | 14,056,853Source | 34,216,000Source | 18,330,000Source | 41,464,000Source | 17,360,000Source | 125,607,000Source | 62,638,025Source | 48,957,788Source | 30,685,642Source |
| Operating Lease, ExpenseUSD | — | — | — | 51,000Source | — | 52,000Source | — | 50,000Source | — | 204,000Source | 207,000Source | 208,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 2,618,561Source | 336,646Source |
| Payments of Financing CostsUSD | — | — | 49,192Source | — | — | — | 135,000Source | 0Source | 188,000Source | — | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 5,000,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 6,762,000Source | 7,788,000Source | 18,881,587Source | 12,949,110Source | 17,769,616Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,179,000Source | 350,000Source | 6,389,000Source | 7,724,129Source | 287,738Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | -4,511Source | — | -4,830Source | 9,683Source | 5,055Source |
| Depreciation, Depletion and Amortization | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 311,709,000Source | 43,472,170Source | — | 65,408Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | — | —Source | —Source | —Source | —Source | —Source | — | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 35,802,663Source | 20,006,093Source |
| Operating Income (Loss)USD | — | — | 51,345,966Source | -3,287,336Source | 42,910,000Source | 19,544,000Source | 63,658,000Source | 20,125,000Source | 150,141,000Source | -22,356,389Source | -48,957,788Source | -30,623,968Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 2,618,561Source | 336,646Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 52,576,178Source | -2,776,812Source | 38,733,000Source | 20,350,000Source | 55,645,000Source | 20,644,000Source | 150,016,000Source | -19,324,790Source | — | -30,287,322Source |
| Income Tax Expense (Benefit)USD | — | — | -55,986,802Source | — | 12,745,000Source | 522,000Source | 17,044,000Source | 0Source | -13,039,000Source | -1,394,770Source | — | -585,617Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 108,562,980Source | -2,776,812Source | 25,988,000Source | 19,828,000Source | 38,601,000Source | 20,644,000Source | 163,055,000Source | -17,930,020Source | -46,339,227Source | -29,701,705Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.42Source | -0.05Source | 0.33Source | 0.29Source | 0.48Source | 0.32Source | 2.25Source | -0.3Source | -0.91Source | -0.74Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.26Source | -0.05Source | 0.29Source | 0.28Source | 0.43Source | 0.3Source | 2.04Source | -0.3Source | -0.91Source | -0.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 75,930,243Source | 58,825,221Source | 78,444,000Source | 67,928,000Source | 79,509,000Source | 65,244,000Source | 72,034Source | 58,871,582Source | 50,902,931Source | 40,274,273Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 86,214,170Source | 58,825,221Source | 92,479,000Source | 71,919,000Source | 92,985,000Source | 68,975,000Source | 80,308Source | 58,871,582Source | 50,902,931Source | 40,274,273Source |
| Interest Expense (non-operating)USD | — | — | 948,242Source | 10,007Source | — | 6,671Source | — | 10,007Source | 2,782,000Source | 36,405Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 3,600,000Source | — | — | — | — | 51,948Source | 13,872,000Source | 155,844Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 12,758,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -72,727Source | -33,325Source | — | -16,295Source | — | -38,172Source | -52,000Source | -30,788Source | -28,994Source | 37,145Source |
| General and Administrative ExpenseUSD | — | — | 25,451,017Source | 6,580,834Source | 15,085,000Source | 9,504,000Source | 21,720,000Source | 9,693,000Source | 68,220,000Source | 29,959,150Source | — | — |
| Gross ProfitUSD | — | — | 93,080,673Source | 10,769,517Source | 77,126,000Source | 37,874,000Source | 105,122,000Source | 37,485,000Source | 275,748,000Source | 40,281,636Source | — | 61,674Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | 52,576,178Source | -2,776,812Source | 38,733,000Source | 20,350,000Source | 55,645,000Source | 20,644,000Source | 150,016,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | 2,029,000Source | — | — | 1,700,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 150,016,000Source | -19,065,449Source | -45,946,020Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -46,339,227Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 34,296Source | 26,515Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | 1,395,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | 2,681,851Source | 326,016Source |
| Investment Income, InterestUSD | — | — | 1,560,272Source | 553,856Source | — | 828,949Source | — | 566,797Source | 3,846,000Source | 2,578,792Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,230,212Source | 510,524Source | -4,177,000Source | 806,000Source | -8,013,000Source | 519,000Source | -125,000Source | 3,031,599Source | — | — |
| Operating ExpensesUSD | — | — | 41,734,707Source | 14,056,853Source | 34,216,000Source | 18,330,000Source | 41,464,000Source | 17,360,000Source | 125,607,000Source | 62,638,025Source | 48,957,788Source | 30,685,642Source |
| Operating Lease, ExpenseUSD | — | — | — | 51,000Source | — | 52,000Source | — | 50,000Source | — | 204,000Source | 207,000Source | 208,000Source |
| Research and Development ExpenseUSD | — | — | 5,097,644Source | 727,119Source | 6,684,000Source | 2,442,000Source | 7,212,000Source | 3,193,000Source | 19,333,000Source | 3,942,270Source | 13,155,125Source | 10,679,549Source |
| Selling and Marketing ExpenseUSD | — | — | 11,186,046Source | 6,748,900Source | 12,447,000Source | 6,384,000Source | 12,532,000Source | 4,474,000Source | 38,054,000Source | 28,736,605Source | — | — |
| Total Revenue | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
ea031153201ex99-1.htm · DEFA14A · 2026-11-10
Exhibit 99.1 FINAL TRANSCRIPT 2026-11-09 CorMedix Inc (CRMD US Equity) Acquisition of Heron Therapeutics by CorMedix Therapeutics Company Participants Joseph Todisco “Joe”, Chairman/CEO Other Participants Brandon Folkes, Analyst, HC Wainwright & Co Jason Butler, Analyst, Citizens Leonid Timashev, Analyst, RBC Capital Leszek Sulewski, Analyst, Oppenheimer & Co. Inc. Serge Belanger, Analyst, Needham Presentation Operator Good afternoon, and welcome …
Read attachment ↗ea031153201ex99-2.htm · DEFA14A · 2026-11-10
Exhibit 99.2 Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1 Disclaimer NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Forward - Looking Statements: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “c…
Read attachment ↗ea031153201ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 FINAL TRANSCRIPT 2026-11-09 CorMedix Inc (CRMD US Equity) Acquisition of Heron Therapeutics by CorMedix Therapeutics Company Participants Joseph Todisco “Joe”, Chairman/CEO Other Participants Brandon Folkes, Analyst, HC Wainwright & Co Jason Butler, Analyst, Citizens Leonid Timashev, Analyst, RBC Capital Leszek Sulewski, Analyst, Oppenheimer & Co. Inc. Serge Belanger, Analyst, Needham Presentation Operator Good afternoon, and welcome …
Read attachment ↗ea031153201ex99-2.htm · 8-K · 2026-11-10
Exhibit 99.2 Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1 Disclaimer NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Forward - Looking Statements: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “c…
Read attachment ↗ea031142301ex99-1.htm · DEFA14A · 2026-11-09
Exhibit 99.1 CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products - ZYNRELEF ®, APONVIE ®, CINVANTI ® and SUSTOL ® - to CorMedix’s hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional consid…
Read attachment ↗ea031142301ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products - ZYNRELEF ®, APONVIE ®, CINVANTI ® and SUSTOL ® - to CorMedix’s hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional consid…
Read attachment ↗